Device Investigational Plan Guidance

A Device Investigational Plan is required when an investigation is not exempt from IDE Device regulations. For more guidance of exemption criteria, please see the guidance Research with Device Products available online here: https://irb.upenn.edu/mission-institutional-review-board-irb/guidance/types-research.

A standalone protocol is also required when an investigation is not exempt from IDE Device regulations. The HSERA IRB application may not serve as the IRB protocol for these types of studies. The following template should be utilized: Protocol Template- Clinical Trial which is available for download online here: https://irb.upenn.edu/forms.

A Device Investigational Plan consists of the following three parts and are detailed below:
1. Sections that are likely to, and should be, covered in the protocol that is submitted to the IRB.
2. Sections / documents that are a required part of the Investigational Plan but are unlikely to be covered in the protocol and require submission to the IRB.
3. Sections / documents that are unlikely to be covered in the protocol and do not require submission to the IRB. These should be maintained in your study records.

<table>
<thead>
<tr>
<th>Name of Device</th>
<th>Manufacturer</th>
<th>Marketing Status in the U.S.</th>
<th>FDA Device Classification (I, II, III)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name</td>
<td>Manufacturer's Name</td>
<td>K########</td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Manufacturer's Name</td>
<td>PMA#####</td>
<td></td>
</tr>
</tbody>
</table>

Part 1

Sections of the Investigational Plan that are likely to, and should be, covered in the protocol that is submitted to the IRB:
- Investigational objectives
- Rationale for conducting the investigation
- Information about prior investigations with the device
- Duration of the study
- Methodology to be used
- A general device description of all devices, instruments, etc. being used in the protocol. For any devices that are not exempt from IDE regulations, a Research with Devices form must also be submitted to the IRB, as outlined in the guidance linked above.

- Analysis demonstrating the protocol is scientifically sound.
- A description of the patient population including the number, age, sex, and condition.

Version 2020/10
• **IDE Required Records:** Description of records that will be maintained in compliance with IDE regulations.
  o **Device accountability:** i.e. records of shipment & disposition of the device
  o **Adverse device effects** (whether anticipated or unanticipated)
• **IDE Required Reports:** Description of reports that will be maintained in compliance with IDE regulations.
  o Reporting of unanticipated adverse device effects to the FDA and IRB
  o Reporting to FDA and IRB, if an investigator failed to obtain consent
  o Reporting to FDA if an IRB withdraws approval for the study
  o Reporting to IRB and FDA of any device recall, repair, or disposal
  o Reporting to IRB and submission to FDA if the device determination is changed to significant risk from non-significant risk
• **Quality Control Plan:** Include the procedures for quality control /GCP monitoring
• **Safety Monitoring Plan:** Include the procedures for medical monitoring as well as any plans for utilizing an independent DSMB/DSMC

### Part 2

Sections / documents that are a required part of the Investigational Plan but are unlikely to be covered in the protocol and **require submission to the IRB:**

- **Device instructions for use:** For each product provide a copy of the instructions.
- **Informed Consent and all informational materials** to be provided to subjects
- **Risk Analysis:** The sponsor-investigator is responsible for identifying risks and for determining which risks to accept and which risks require mitigation. The sponsor-investigator is also responsible for evaluating identified risks against risk mitigating strategies.

The Risk Analysis should consist of a detailed assessment of the risk likelihood to the subjects and risk consequences, and how these risks will be mitigated. Please refer to the tables below. This should include the risk of the device(s) generally, any risks with combining devices (if applicable), risks specific to the participant population being studied, and other risks in the trial related to other procedures.
Example Risk Analysis:

<table>
<thead>
<tr>
<th>Participant Risk</th>
<th>Risk Likelihood</th>
<th>Risk Consequence</th>
<th>Mitigation Y/N</th>
<th>Mitigation Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Risk 1</td>
<td>Expected</td>
<td>Moderate Health Hazard</td>
<td>Y</td>
<td>Risk mitigation strategy</td>
</tr>
<tr>
<td>Risk 2</td>
<td>Unlikely</td>
<td>No Health Hazard</td>
<td>N</td>
<td>N/A</td>
</tr>
</tbody>
</table>
Part 3

Sections / documents that are unlikely to be covered in the protocol and do not require submission to the IRB but **should be maintained in your study records. The IRB withholds the right to request any of this documentation.**

- **Detailed Device Description:** Description of each important component, ingredient, property, and principle of operation of the device and any anticipated changes in the device during the investigation.
- A device description that includes any applicable predicate devices, approved uses of the device, and use on the protocol
  - A predicate is a medical device that may be legally marketed in the U.S. and is used as a point of comparison for new medical devices
- **Device engineering designs and related documents**
- **Name and Contact Information for the following:**
  - **Site Information:** The name and address of each institution at which a part of the investigation may be conducted (that has not been identified in any other section of the Investigational Plan).
  - **Quality Control Monitor:** Name and address
  - **Safety Monitoring Designee:** Name and address
  - **IRB:** Include a list of the names, locations, and chairpersons of all IRBs that have been or will be asked to review the investigation
  - **Clinical Laboratory Facilities:** Name and address
- **Investigator Documentation:** Signed Investigator Agreement(s)
- **IDE Sponsor Required Records:**
  - All correspondence with, for example, another sponsor, a monitor or vendor, an investigator, an IRB, or FDA, including required reports.
  - Adverse device effects (whether anticipated or unanticipated) and subject complaints
  - Document the device manufacturer’s level of GMP compliance (requirements in 21 CFR 820)
- **Clinical Trials.gov (42 CFR 11)**
  - Register, maintain, and provide results of your trial listing on Clinical Trials.gov.
- **Device Packaging / Labelling (as per 21 CFR 812.5):** Ensure the device is appropriately labeled with the following statement: "CAUTION--Investigational device. Limited by Federal (or United States) law to investigational use."

**ADDITIONAL INFORMATION**

Guidance on [Requirements for Abbreviated IDE Holders](#) from the PSOM Office of Clinical Research

For additional assistance, please contact: the Penn Medicine [Office of Clinical Research, Sponsor Support Unit](#).